Renascience

Renascience Net Change in Cash

The Net Change in Cash of Renascience (4889.T) as of Nov 19, 2026 is 1.60 B JPY. In the previous year, Net Change in Cash was 153.62 M JPY — a change of 943.39% (higher).

Net Change in Cash

1.60 BJPY

YoY

943.39%

Last updated:

Net Change in Cash of Renascience is 2026 1.60 B JPY. Net Change in Cash of Renascience was 2025 153.62 M JPY. It decreases by 943.39% higher compared to the previous year.

The Renascience Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2020
-179.01 M JPY
Jan 1, 2021
44.68 M JPY
Jan 1, 2022
1.36 B JPY
Jan 1, 2023
-174.04 M JPY
Jan 1, 2024
-185.59 M JPY
Jan 1, 2025
153.62 M JPY
Jan 1, 2026
1.60 B JPY
The Renascience Net Change in Cash history
YEARNet Change in CashYoY
1.60 BJPY+943.39%
153.62 MJPY-182.78%
-185.59 MJPY+6.64%
-174.04 MJPY-112.79%
1.36 BJPY+2,946.16%
44.68 MJPY-124.96%
-179.01 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Net Change in Cash of Renascience is 1.60 B JPY in 2026.

Net Change in Cash of Renascience changed from 153.62 M JPY to 1.60 B JPY, representing a 943.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Renascience since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Renascience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience